The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center

American Surgeon

Volumn 77, Issue 8, 2011, Pages 1043-1049

  Morse, Bryan C ^a   Dente, Christopher J ^a   Hodgman, Erica I ^a   Shaz, Beth H ^a   Nicholas, Jeffrey M ^a   Wyrzykowski, Amy D ^a   Salomone, Jeffrey P ^a   Vercruysse, Gary A ^a   Rozycki, Grace S ^a   Feliciano, David V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL PROTOCOL; CONTROLLED STUDY; CRYOPRECIPITATE; EMERGENCY HEALTH SERVICE; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; EXSANGUINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ADULT; BLOOD TRANSFUSION; CRITICAL CARE; DATABASES, FACTUAL; FACTOR VIIA; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HOSPITAL MORTALITY; HOSPITALS, UNIVERSITY; HUMANS; MALE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TRAUMA CENTERS; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 80052074739     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rotondo MF, Schwab CW, McGonigal MD, et al. 'Damage control': An approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma 1993;35:375-82, discussion 382-3.
2. Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: Directly addressing the early coagulopathy of trauma. J Trauma 2007;62:307-10.
3. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007;63:805-13. (Pubitemid 350287298)
4. Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008;248:447-58.
5. Stinger HK, Spinella PC, Perkins JG, et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008;64(2 Suppl):S79-85; discussion S85.
6. Perkins JG, Cap AP, Spinella PC, et al. An evaluation of the impact of apheresis platelets used in the setting of massively transfused trauma patients. J Trauma 2009;66(4 Suppl):S77-84; discussion S84-5.
7. Zink KA, Sambasivan CN, Holcomb JB, et al. A high ratio of plasma and platelets to packed red blood cells in the first 6 hours of massive transfusion improves outcomes in a large multicenter study. Am J Surg 2009;197:565-70, discussion 570.
8. Shaz BH, Dente CJ, Nicholas J, et al. Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion 2010;50:493-500.
9. Dente CJ, Shaz BH, Nicholas JM, et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian Level I trauma center. J Trauma 2009;66:1616-24.
10. Dente CJ, Shaz BH, Nicholas JM, et al. Early predictors of massive transfusion in patients sustaining torso gunshot wounds in a civilian Level I trauma center. J Trauma 2010;68:298-304.
11. Mohr AM, Holcomb JB, Dutton RP, et al. Recombinant activated Factor VIIa and hemostasis in critical care: A focus on trauma. Crit Care 2005;9(Suppl 5):S37-42. (Pubitemid 43173687)
12. Kenet G, Walden R, Eldad A, et al. Treatment of traumatic bleeding with recombinant Factor VIIa. Lancet 1999;354:1879.
13. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated Factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-8, discussion 438-9.
14. Martinowitz U, Holcomb JB, Pusateri AE, et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001;50:721-9. (Pubitemid 32336261)
15. O'Neill PA, Bluth M, Gloster ES, et al. A successful use of recombinant activated Factor VII for trauma- Associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002;52:400-5. (Pubitemid 34183816)
16. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004;57:709-18, discussion 718-9.
17. Dutton RP, Hess JR, Scalea TM. Recombinant Factor VIIa for control of hemorrhage: Early experience in critically ill trauma patients. J Clin Anesth 2003;15:184-8. (Pubitemid 36593444)
18. Boffard KD, Riou B, Warren B, et al. Recombinant Factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005;59:8-15, discussion 15-8.
19. Hauser CJ, Boffard K, Dutton R, et al. Results of the CONTROL trial: Efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma 2010;69:489-500.
20. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006;124:747-57. (Pubitemid 44066599)
21. Spinella PC, Perkins JG, McLaughlin DF, et al. The effect of recombinant activated Factor VII on mortality in combat- Related casualties with severe trauma and massive transfusion. J Trauma 2008;64:286-93. (Pubitemid 351640428)
22. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation Factor VIIa. JAMA 2006;295:293-8. (Pubitemid 43112957)
23. Thomas GO, Dutton RP, Hemlock B, et al. Thromboembolic complications associated with Factor VIIa administration. J Trauma 2007;62:564-9. (Pubitemid 46568851)